Literature DB >> 31101648

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin.

Sarah L Reeves1,2, Hannah K Jary1, Jennifer P Gondhi1, Mary Kleyn3, Kevin J Dombkowski1.   

Abstract

The health effects of sickle cell trait among children are unknown. We compared select health outcomes and health services utilization among children with sickle cell trait, sickle cell anemia (SCA), and normal hemoglobin. Newborn screening records were used to identify children with sickle cell trait and SCA born in Michigan (1997-2014) who were enrolled in Michigan Medicaid for ≥1 year from 2012 to 2014. Each select health outcome (acute otitis media, acute respiratory infections, fever, invasive pneumococcal disease, pneumonia and influenza, renal complications, spleen problems, stroke) was defined as ≥1 claim with a diagnosis code for the respective outcome within a study year. Health services utilization was summarized as counts of emergency department, inpatient, and outpatient encounters. The relationship between hemoglobin status and each health outcome or utilization was assessed by logistic or negative binomial regression with generalized estimating equations. The study population consisted of 18 257 children with sickle cell trait, 368 with SCA, and 74 523 with normal hemoglobin (227 188 total person-years). Compared with those with normal hemoglobin, children with sickle cell trait had lower odds of acute otitis media (odds ratio [OR], 0.88; 95% confidence interval [CI], 0.84-0.91), acute respiratory infections (OR, 0.94; 95% CI, 0.92-0.97), pneumonia and influenza (OR, 0.93; 95% CI, 0.87-0.99), and outpatient visits (incidence rate ratio, 0.95; 95% CI, 0.93-0.97). Children with SCA had higher or nonsignificant odds of all outcomes and types of health services utilization. These results indicate that children with sickle cell trait may not be at additional health risk for these outcomes. However, additional case-control studies may be necessary to identify rare events.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31101648      PMCID: PMC6538867          DOI: 10.1182/bloodadvances.2018028043

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  51 in total

1.  Framing the research agenda for sickle cell trait: building on the current understanding of clinical events and their potential implications.

Authors:  Jonathan C Goldsmith; Vence L Bonham; Clinton H Joiner; Gregory J Kato; Allan S Noonan; Martin H Steinberg
Journal:  Am J Hematol       Date:  2012-02-03       Impact factor: 10.047

2.  Communication of positive newborn screening results for sickle cell disease and sickle cell trait: variation across states.

Authors:  Patricia L Kavanagh; C Jason Wang; Bradford L Therrell; Philippa G Sprinz; Howard Bauchner
Journal:  Am J Med Genet C Semin Med Genet       Date:  2008-02-15       Impact factor: 3.908

Review 3.  Pulmonary complications of sickle cell disease.

Authors:  Mark T Gladwin; Elliott Vichinsky
Journal:  N Engl J Med       Date:  2008-11-20       Impact factor: 91.245

Review 4.  Complications associated with sickle cell trait: a brief narrative review.

Authors:  Geoffrey Tsaras; Amma Owusu-Ansah; Freda Owusua Boateng; Yaw Amoateng-Adjepong
Journal:  Am J Med       Date:  2009-04-24       Impact factor: 4.965

5.  Sickle cell trait and development of microvascular complications in diabetes mellitus.

Authors:  Anthony J Bleyer; Sri V Reddy; Leon Sujata; Gregory B Russell; Damilola Akinnifesi; Anthony J Bleyer; Donald Hire; Zak Shihabi; Mary Ann Knovich; Pirouz Daeihagh; Jorge Calles; Barry I Freedman
Journal:  Clin J Am Soc Nephrol       Date:  2010-03-18       Impact factor: 8.237

6.  Benign sickle-cell anaemia.

Authors:  R P Perrine; M J Brown; J B Clegg; D J Weatherall; A May
Journal:  Lancet       Date:  1972-12-02       Impact factor: 79.321

7.  Sickle cell "nondisease". A potentially serious public health problem.

Authors:  M L Hampton; J Anderson; B S Lavizzo; A B Bergmen
Journal:  Am J Dis Child       Date:  1974-07

8.  The risk of potential thromboembolic, renal and cardiac complications of sickle cell trait.

Authors:  Matthew D Bucknor; Jeanna S Goo; Michael L Coppolino
Journal:  Hemoglobin       Date:  2013-10-07       Impact factor: 0.849

9.  Splenic syndrome at mountain altitudes in sickle cell trait. Its occurrence in nonblack persons.

Authors:  P A Lane; J H Githens
Journal:  JAMA       Date:  1985-04-19       Impact factor: 56.272

10.  Healthcare utilization and expenditures for low income children with sickle cell disease.

Authors:  Jean L Raphael; Craig L Dietrich; Deborah Whitmire; Donald H Mahoney; Brigitta U Mueller; Angelo P Giardino
Journal:  Pediatr Blood Cancer       Date:  2009-02       Impact factor: 3.167

View more
  5 in total

1.  Correction of murine sickle cell disease by allogeneic haematopoietic cell transplantation with anti-3rd party veto cells.

Authors:  Aloukick Kumar Singh; Elias Schetzen; Sandeep Kumar Yadav; Esther Bachar Lustig; Wei-Hsin Liu; Raj Kumar Yadav; Robert Peter Gale; Kathryn McGinnis; Yair Reisner
Journal:  Bone Marrow Transplant       Date:  2021-03-03       Impact factor: 5.174

2.  COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals.

Authors:  Ashima Singh; Amanda M Brandow; Julie A Panepinto
Journal:  Blood Adv       Date:  2021-04-13

3.  COVID-19 Vaccine Perception and Hesitancy Among Patients With Sickle Cell Disease in the Western Region of Saudi Arabia.

Authors:  Hamza Jan; Abdullah Waheeb; Hatem AlAhwal; Abdullah Almohammadi; Adel Al-Marzouki; Ahmed Barefah; Salem Bahashawan; Osman Radhwi
Journal:  Cureus       Date:  2022-01-08

4.  Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease.

Authors:  Lana Mucalo; Amanda M Brandow; Mahua Dasgupta; Sadie F Mason; Pippa M Simpson; Ashima Singh; Bradley W Taylor; Katherine J Woods; Fouza I Yusuf; Julie A Panepinto
Journal:  Blood Adv       Date:  2021-07-13

5.  Health services use by children identified as heterozygous hemoglobinopathy mutation carriers via newborn screening.

Authors:  Sara D Khangura; Beth K Potter; Christine Davies; Robin Ducharme; A Brianne Bota; Steven Hawken; Kumanan Wilson; Maria D Karaceper; Robert J Klaassen; Julian Little; Ewurabena Simpson; Pranesh Chakraborty
Journal:  BMC Pediatr       Date:  2021-07-01       Impact factor: 2.125

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.